Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GMan, You're quite welcome. Don't let anyone mislead you into thinking almost no one owns shares in this or other stocks. Been in this game for a few years.
Not saying that you are a newbie, but some folks feed you information which is inaccurate and much more in their interest than yours.
Sometimes inexperienced investors get confused as to the number of shareholders companies like ROX has.
When counting shareholders, the hundreds of us who hold our shares at Fidelity are shown as just ONE shareholder of record. Same is true for those at TD, Morgan Stanley, etc. ONE shareholder of record - the brokerage house - is all that is shown. Since your shares are held in "street name" whether they are in a cash account, margin account, IRA or whatever, you can put in your order and sell on the spot. Or buy as the case may be.
On the other hand, if you get your shares delivered to you in certificate form YOU count as one shareholder. Of course, if you do this and want to sell your shares, you have to get the signed certificate back to the broker, wait three days for the shares to be put into street name and only then can you sell.
Even tho I am a long term holder of ROX, I still like the security of keeping them at the broker. I lost a certificate once, roughly 50 years ago, and I had to go thru a whole long process to certify that and get a replacement.
Let's hope all the long-term longs in CTIX are around to collect on it's full promise.
You may need to walk your neighbor out of the hospital to make sure they are steady on their feet.
Early negotiations for a partnership or buyout could account for the delay. Would be one hell of an announcement for the SP.
TORONTO, Oct. 6, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has rescheduled its Annual and Special Meeting of Shareholders to Thursday, December 15, 2016 at Mount Royal University, Roderick Mah Centre for Continuous Learning (Room EC1040), 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at 9:00 am (MDT). A notice of meeting and management information circular containing the matters to be considered at the meeting will be delivered to shareholders and filed on SEDAR at www.sedar.com on or before November 15, 2016.
Following the formal business of the meeting, Mr. Donald J. McCaffrey, President and Chief Executive Officer, will deliver a corporate presentation which will be webcast.
Webcast Details:
Date: Thursday, December 15, 2016
Time: Approximately 9:30 am MDT
Webcast Link: http://services.choruscall.ca/links/resverlogixagm20161215.html
Gov, It is a legitimate email sent to all holders of BIVI. You are under no obligation to buy more shares. It's just an offering.
Gman, Hey, I don't get to wear my tux?
But, were they wearing Bermuda shorts?
The amount was "close enough" so I sold all of mine. Wife is happy. Daughter is happy.
Now to find new mountains to climb. Your suggestions?
From Caskers:
Jefferson's Chef Collaboration Straight Whiskey
Made in collaboration with Chef Edward Lee, this whiskey pays homage to Thomas Jefferson.
$59.99
The principal author of the Declaration of Independence and one of the greatest Founding Fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westward in order to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated on his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to distill the excess grains they harvested from their farms into spirits (George Washington was one of the country's largest distillers of rye whiskey). As a result, each farmer's spirits were unique and reflected the local terrior of their farm.
Made in collaboration with Chef Edward Lee of 610 Magnolia and Milkwood restaurants in Louisville, Jefferson's Chef Collaboration Straight Whiskey pays homage to the spirits Jefferson distilled over two centuries ago. "We started to think about what foods would pair well with bourbon," says Trey Zoeller, Jefferson's founder and master blender. "When we started to think about pairing whiskey with some dishes from Chef Lee's cookbook — pork dishes, spicier dishes, and his fried chicken particularly — it really came together."
Crafted from a blend of straight bourbon and rye whiskies, Jefferson's Chef Collaboration has an aroma of cherry, dried citrus and oak that gives way to notes of buttered biscuits, peaches and tart apples on the palate. Subtle touches of rye bread and spicy oak tannins linger, and lead to a finish accented by touches of citrus and cloves.
We have only a handful of bottles of this whiskey available. Pick one up today!"
Financials now on Yahoo:
http://finance.yahoo.com/quote/bivi/financials?ltr=1
IMHO, I expect they will need to sell more shares to move drug tests forward.
I noticed but he also buys his flagship company shares virtually every day.
Have FUN and report back!
From annual report (p 44) Leo still owns stock:
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information concerning the ownership of the Common Stock by (a) each person who, to the best of our knowledge, beneficially owned on that date more than 5% of our outstanding Common Stock, (b) each of our Directors and executive officers and (c) all current Directors and executive officers as a group. The following table is based upon an aggregate of 87,160,001 shares of our Common Stock outstanding as of the date of this prospectus.
Name and Address of Beneficial Owner Number of Shares of Common Stock Beneficially Owned or Right to Direct Vote (1) Percent of Common Stock Beneficially Owned or Right to Direct Vote (1)
Jonathan Adams 6,168,066 7.1 %
Amrit Shahzad 1,298,512 1.5 %
Cuong Do 2,671,354 3.1%
All Directors and executive officers as a group (Three persons): 10, 137, 932 11.6%
Other 5% or Greater Beneficial Owners:
Elliot Ehrlich
9511 Collins Ave #807 Surfside, FL 33154
7,400,000
8.5 %
Leo and Helene Ehrlich (2)
7846 Tennyson Ct. Boca Raton, FL 33433
8,500,000 9.75 %
Rebecca Guttman (2)
655 Ibsen St., Woodmere, NY 11598
8,500,000 9.75 %
RGN Brothers Trust 8,500,000 9.75%
_________________________________
From the annual report (pp 41-42):
"ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Set forth below is certain information concerning the directors and executive officers of the Company.
Name Age Position
Jonathan Adams 53 Chief Executive Officer and Chief Financial Officer
Amrit Shahzad
Cuong Do
60
51
President and Secretary
Independent Director
According to our Bylaws, the directors shall be elected at the annual meeting of the stockholders and each director shall be elected to serve until his successor shall be elected and shall qualify. A director need not be a stockholder. Directors shall not receive any stated salary for their services as directors or as members of committees, but by resolution of the Board a fixed fee and expenses of attendance may be allowed for attendance at each meeting. The Bylaws shall not be construed to preclude any director from serving the Company in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.
There are no familial relationships among any of our Directors or officers. None of our Directors or officers is or has been a Director or has held any form of directorship in any other U.S. reporting companies except as mentioned above. None of our Directors or officers has been affiliated with any company that has filed for bankruptcy within the last five years. The Company is not aware of any proceedings to which any of the Company’s Officers or Directors, or any associate of any such officer or Director, is a party that are adverse to the Company. We are also not aware of any material interest of any of our officers or directors that is adverse to our own interests.
Information
Mr. Jonathan Adams has served as the Company’s Chief Executive Officer and Chief Financial Officer since it acquired LAT Pharma LLC on April 11, 2016. He founded LAT Pharma LLC and served as its Chief Executive Officer prior to its acquisition. Mr. Adams has over 26 years of biopharmaceutical industry experience, including corporate finance, company acquisitions and licensing deals, marketing and sales support. At Searle Pharmaceuticals he was a member of the global launch team for Celebrex, and he has worked on launching numerous new drugs and medical devices. Mr. Adams earned a BS at Cornell University and an MBA at the Tuck School at Dartmouth.
Ms. Amrit Shahzad has served as the Company’s President and Secretary since it acquired LAT Pharma LLC on April 11, 2016. Ms. Shahzad has worked in the biopharmaceutical industry for more than 25 years. Prior to starting her own consulting firm in 2014, she worked in a variety of leadership roles at Roche, Amgen and Ikaria, and has been on the board of several startup companies. She has extensive business and corporate development experience including corporate venture funds. Her transactional experience spans multiple therapeutic areas, technologies, and platforms. Ms. Shahzad holds a medical degree (MBBS) from Lady Hardinge Medical College in New Delhi, India, and an MBA from Rutgers University.
Mr. Cuong Do is currently Executive Vice President, Global Strategy Group, at Samsung. Mr. Do helps to set the strategic direction for Samsung Group’s diverse business portfolio. He was previously the Chief Strategy Officer for Merck, a leading US pharmaceuticals company, Tyco Electronics, and Lenovo. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years and helped build the healthcare, high tech and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.
Qualifications
Jonathan Adams’s qualifications to serve on our Board of Directors are primarily based on his founding of LAT Pharma LLC and his over 26 years of biopharmaceutical industry experience. As Chief Executive of LAT Pharma LLC, Mr. Adams worked to develop CIPT Technology and secured Orphan Drug Designation for a BIV201 analogue (this new drug candidate is no longer in development). Mr. Adams’s biopharmaceutical experience includes work in corporate finance, company acquisitions and licensing deals, marketing and sales support.
Amrit Shahzad’s qualifications to serve on our Board of Directors are primarily based on her more than 25 years of biopharmaceutical industry experience. Prior to starting her own consulting firm in 2014, Ms. Shahzad worked in a variety of leadership roles at Roche, Amgen and Ikaria, and has been on the board of several startup companies. She has extensive business and corporate development experience including corporate venture funds. Her transactional experience spans multiple therapeutic areas, technologies, and platforms.
Cuong Do’s qualifications to server on our Board of Directors are primarily based on his decades of experience as an executive in the pharma, biotech, and other high technology industries. . He was previously the Chief Strategy Officer for Merck, a leading US pharmaceuticals company, Tyco Electronics, and Lenovo. Mr. Do is a former senior partner at McKinsey & Company, where he spent 17 years and helped build the healthcare, high tech and corporate finance practices. "
From the annual report (p 38):
"8. Stock Options
In connection with the employment agreement signed with the Chief Financial Officer on April 11, 2016, Jonathan Adams was granted options to acquire 3 million shares exercisable at $0.06 per share, the closing price on that date. These Options Group A shall become vested and exercisable (i) as to 1 million shares on April 11, 2017, (ii) as to 1 million shares on April 11, 2018, and (iii) as to 1 million shares on April 11, 2019. "
From the annual report (p 37):
"7. Purchase of LAT Pharma
On April 11, 2016, the Company entered into and consummated an Agreement and Plan of Merger (the “Merger Agreement”), with LAT Acquisition Corp., a Nevada corporation and wholly-owned subsidiary of the Company (“Acquisition”) and LAT Pharma, LLC an Illinois limited liability company (“LAT”). Pursuant to the terms of the Merger Agreement, Acquisition merged with and into LAT in a statutory triangular merger (the “Merger”) with LAT surviving as a wholly-owned subsidiary of the Company. As consideration for the Merger, the Company issued the interest holders of LAT (the “LAT Holders”) an aggregate of 39,820,000 shares of our Common Stock issued to the LAT Holders in accordance with their pro rata ownership of LAT membership interests prior to the Merger. Following the Merger, the Registrant will continue the development of LAT’s lead clinical therapeutic candidate Continuous low-dose Infusion (CI) Terlipressin.
Immediately prior to the Merger, the Company had 87,210,000 shares of Common Stock issued and outstanding. In connection with the Merger, certain shareholders of the Company collectively agreed to retire and cancel an aggregate of 39,869,999 shares of Common Stock. Following the consummation of the Merger, the issuance of the Merger Shares of the 39,820,000 shares of Common Stock, the Company had 87,160,001 shares of Common Stock issued and outstanding and the LAT Holders beneficially own 39,820,000 shares or approximately forty-six percent (46%) of such issued and outstanding Common Stock.
Under the purchase method of accounting, the transaction was valued for accounting purposes at $2,389,200, which was the estimated fair value of the consideration paid by the Company. The estimate was based on the consideration paid of 39,820,000 shares of common stock valued based on the closing price on 04/11/2016 of $0.06 per share."
New annual report:
" We are a development stage biotechnology company engaged in the discovery, development and commercialization of a therapy targeting ascites due to liver cirrhosis. Ascites due to liver cirrhosis is a life-threatening condition affecting about 100,000 Americans and many times more worldwide. Our therapy BIV201 is based on a drug that is approved in about 50 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. BIV201's active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients. We are currently completing the work necessary to file our investigational new drug (IND) application, and aim to commence clinical trials should the FDA approve our application. The Company's activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the company's business plan.
We have incurred $432,028 of operating expenses for the year ended June 30, 2016. We are now engaged in organizational activities and sourcing compounds and materials. We anticipate incurring other costs associated with equipment purchases and general and administrative expenses, including employee salaries and benefits, legal expenses, and other costs associated with an early stage, publicly-traded company.
The amounts that we actually spend for any specific purpose may vary significantly, and will depend on a number of factors including, but not limited to, the pace of progress of our research and development, market conditions, and our ability to qualify vendors. In addition, we may use a portion of any net proceeds to acquire complementary compounds; however, we do not have plans for any acquisitions at this time. We will have significant discretion in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of our Common Stock.
Requirement for Additional Capital
The Company has engaged in limited research and development activities. We currently do not have sufficient funds to meet our planned drug development for the next twelve (12) months and we may not be able to obtain the necessary financing on terms and conditions acceptable to the Company. Assuming that we are successful in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:
? Research and Development of $45,000, which includes planned costs for the development of BIV201.
? Corporate overhead of $15,000, which includes budgeted legal, accounting and other costs expected to be incurred; and
? Staffing costs of $250,000.
The Company had approximately $123,757 of cash on hand at June 30, 2016 and will be unable to proceed with its planned drug development, meet its administrative expense requirements, capital costs, or staffing costs without obtaining additional net financing of approximately $250,000 to $500,000 to meet its near-term budgetary needs.
The Company has limited experience with pharmaceutical drug development. As such these budget estimates may not be accurate. In addition, the actual work to be performed can only be broadly projected, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget. Such changes may also have an adverse impact on our projected timeline of drug development.
Management intends to use capital and debt financing, as required, to fund the Company's operations. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to fund its anticipated obligations for the next twelve (12) months.
Capital Resources and Liquidity
As of June 30, 2016, we had $123,757 of cash on hand in our corporate bank account. The Company is considered to be a development stage company and will continue in the development stage until generating revenues from the sales of its products or services. As a result, the report of the independent registered public accounting firm on our financial statements as of June 30, 2016, contains an explanatory paragraph regarding a substantial doubt about our ability to continue as a going concern.
We do not have sufficient funds for the next (12) twelve months and must raise cash to implement our strategy and stay in business. If we are unable to raise additional funds to develop our compounds, we may be required to scale back our development plans by reducing expenditures for employees, consultants, business development, and other envisioned expenditures. This could reduce our ability to develop BIV201, our drug candidate, and implement our business plan. In that event, investors should anticipate that their entire investment may be lost and there may be no ability to profit from this investment.
We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.
If we are unable to raise additional funds, we will need to do one or more of the following:
? delay, scale-back or eliminate some or all of our research and product development programs;
? provide licenses to third parties to develop and commercialize products or technologies that we would otherwise seek to develop and commercialize ourselves;
? seek strategic alliances or business combinations;
? attempt to sell our company;
? cease operations; or
? declare bankruptcy.
We believe that our existing cash and cash equivalents will not be sufficient to meet our operating and capital requirements until June 30, 2017. Any debt financing secured by us in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to secure additional debt or equity financing in a timely manner, or at all, which could require us to scale back our business plan and operations.
The above conditions raise substantial doubt about our ability to continue as a going concern. The financial statements included elsewhere herein were prepared under the assumption that we would continue our operations as a going concern. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. Without additional funds from debt or equity financing, sales of our intellectual property or technologies, or from a business combination or a similar transaction, we will soon exhaust our resources and will be unable to continue operations. If we cannot continue as a viable entity, our stockholders may lose some or all of their investment in us.
Our management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.
Emerging Growth Company
We are an "emerging growth company" under the federal securities laws and will be subject to reduced public company reporting requirements. In addition,
Section 107 of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards.
Off-Balance Sheet Arrangements
The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company's financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term "off-balance sheet arrangement" generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
We believe that the following critical policies affect our more significant judgments and estimates used in preparation of our financial statements.
Equipment is recorded at cost and depreciated on a declining balance and straight-line basis over their estimated useful lives, principally two to seven years. Accelerated methods are used for tax depreciation. Maintenance and repairs are charged to operations when incurred. Betterments and renewals are capitalized. When furniture and equipment are sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and any gain or loss is included in operations.
Research and development costs are charged to operations when incurred and are included in operating expenses. "
https://biz.yahoo.com/e/160928/bivi10-k.html
Printed proxies and proxy statements arrived Monday 9/26.
I guess the stock took a long weekend off.
So my proxy for voting on the buyout appeared in my Fidelity account yesterday 9/22, with the vote due by 10/12. If you have online voting set up thru your broker, you may want to check to see whether you can vote yet.
Shares in our other accounts get printed proxies, so I can't vote those yet.
No argument. ROX is not YET widely enough held!
Very good advice from Dr. Salt. Seriously.
Fun, does the number of shareholder count all holders in street name under, let's say, Fidelity as ONE holder? I would argue that this is the way it is counted, as there are at least four holders in my family alone. Therefore, those thinking that there are only a few of us are underestimating the potential demand from existing shareholders, let alone those slowly finding out about the ROX story thru efforts of Trey and you and $oldier.
FUNMAN Member Level Wednesday, 09/21/16 10:34:41 AM
Re: Guitarmanlife post# 11293
Post # of 11311
The number of ROX shareholders is actually very small. At June 9, 2016, there were approximately 190 record holders of our common stock.
Aye Aye Cap'n.
Stock, FWIW, if it were Frost it will show up in the SEC insider trades, which Frost is meticulous about filing. To this point I, at least, have seen nothing of the sort.
Furthering our education into spirits:
"By Heather Gordon
Why Sherry Is Your New Drinking Buddy
sherry
Sherry is here, it’s eager, it’s dynamic, and it’s your new partner in crime!
Looked at for years as a wine that your grandmother would likely break out during the holidays, or as a sweet after-dinner drink you would be served at some fancy Valentine’s Day dinner as a ploy to wine your love. I am here to tell you that Sherry is so much more than that! It has been hiding in the shadows, waiting patiently for its moment and I’m stoked to say, I think its time has arrived.
Sherry is a fortified wine, meaning that extra booze was added during the fermentation process. More times than not, the booze added is brandy, but any distilled spirit suffices. Born and raised in Jerez de la Frontera, a town located in the Andalusia region in southern Spain, it is produced through a crazy fractional blending method known as the Solera System. This system involves barrels stacked in a pyramid allowing the wine to transfer from the top barrel down, mixing the wines. The main grape used in sherry production is Palomino, a grape that can be found all over the world and is known for its love to suck in air (meaning oxidation).
I can see you shaking your head rambling on about how you aren’t a dessert person, with a brimming glass of Sancerre in your hand, but listen, there is a wide variety of sherries ranging from dry, savory wines that will make your mouth water to sweet treats that are perfect for those of you who are into drinking your dessert (like me). So don’t write me off just yet! Here is a guide to the sherry basics:
Fino and Manzanilla
The lightest of all the styles, these wines are the bone dry, high acid, savory ocean-water-esque types. It has a fuller, somewhat oily mouth feel and need to be paired with food. Seriously, please do me (and yourself) a favor and hit up Whole Foods, grab some Marcona almonds, Manchego cheese and garlic olives, and you will be able to die peacefully. These wines are awe-inspiring flavor enhancers and need to be treated as such! Manzanilla is very similar to Fino but has a touch more body and a nuttier flavor. Both are gateway sherries, so beware you may get hooked.
Amontillado
AKA an aged Fino Sherry, still a dry wine but richer than the previous styles, clad with a deeper amber color and a warm walnutty, briney aroma. These wines would be paired best with saltier snacks like anchovies, kalamata olives, and cured meats.
Oloroso
This full-bodied sherry with a dark deep golden color tastes like you are eating raisins and prunes while sitting by a fireplace in a ski lodge. The warming qualities are due to its higher alcohol level (usually ranging around 20%). This wine is not as delicate as the Fino Sherries, and instead is big, bold and ready, or the Dwayne ‘The Rock’ Johnson of the sherry world.
Cream & PX
This is the moment you’ve been waiting for! The wrap me up in a 6-foot-long hand-knitted scarf, fuzzy earmuffs in the snow, Drake is writing a rap song about you, sherry. These wines are sweet, decadent, syrup-like treats and more of “just a splash” kind of wine instead of a big pour. Perfect for dessert or to top off your bowl of ice cream. PX is for the person who could eat waffles with whipped cream and strawberries for every meal of the day. Named after Pedro Ximénez, this grape is dried into raisin form before being made into wine.
There are far more levels of sherry out there that we could sit here and spend hours chatting about, but this is a great place to help you fall in love. Whether you are the kind of person who craves a McFlurry or a Slim Jim, there is a sherry out there for you."
http://thebacklabel.com/sherry-is-your-drinking-buddy/#ixzz4Kpcv5aW9
As do we! Or at least we think we do. lol
Once again, Caskers featuring Jeffersons Groth:
Jefferson's Reserve Groth Reserve Cask Finish Very Old Straight Bourbon Whiskey
This limited release was extra-matured in ex-Cabernet Sauvignon barrels from Napa Valley’s Groth Vineyards for nine months.
$114.99 $89.99
The principal author of the Declaration of Independence and one of the greatest Founding Fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westrrtrtward in order to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated on his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to distill the excess grains they harvested from their farms into spirits (George Washington was one of the country’s largest distillers of rye whiskey). As a result, each farmer’s spirits were unique and reflected the local terrior of their farm. The Jefferson’s brand pays homage to Jefferson and the exquisite whiskey he distilled.
Jefferson’s Groth Reserve Cask Finish Bourbon Whiskey was first aged in...
read more
Interesting acquisition, which might be addressed at the major players developing/producing new batteries. I guess this is not the huge partner to which Doug has previously alluded.
Ah well, just because I'm the 12th wonder of the ancient world, I suppose.
Excellent
Not all that many shares traded. But someone was buying whatever was available. Just IMHO.
Difference between Whiskey and Bourbon:
http://thebacklabel.com/difference-whiskey-bourbon/?utm_source=retention_science&utm_medium=email&utm_campaign=sunday_9_11_16&utm_content=cta_text#.V9Xfa62Psto
When navigating the bar whether the top shelf or the well for the special, many see bourbon and whiskey as synonymous. Throw scotch, Irish or Japanese whiskey into the equation and a whole map of brown liquors begins to emerge barely telling the difference other than maybe the glass it’s being served in. So what’s the difference between sipping bourbon on the rocks or having a healthy pour of the regular stuff?
While the two are clearly related, bourbon by definition must follow the law, which is simply a numbers game. The grain mixture, also known as the mash, must be 51 percent corn, and the rest a mix of rye, malted barley, and/or wheat. Then, the fermented mixture must be distilled at no more than 160° proof and stored at no more than 125° proof in new, charred oak casks. No amount of time is required for bourbon to age but numbers can continue to alter the definition. If it is aged for two years or more then it adopts the term “straight” and becomes “straight bourbon whiskey” on the label.
General American whiskeys have a more relaxed law that defines the amber-hued beverage. There is no required percentage of each grain in the fermented mash, even though it will always contain the same ingredients corn, wheat, rye, and/or malted barley. The mixture is distilled at 190° proof or less, in oak containers, and bottled at no less than 80° proof. And, the same rule applies for whiskey when defined at “straight,” it must stay at least 2 years in its barrel.
Production regions have to be the most serious distinguisher between whiskeys produced around the globe with each having specific regulations for the distillation process. Scotch, for example, must be produced in Scotland and is broken into five different categories. One of these is the single malt scotch with a distillation process involving only malted barley and water without the addition of another grain. Japanese whisky is also defined by region with most distillers following Scottish practices, distilling twice and importing malted barley from Scotland. Irish whiskey also echoes the rule of being defined by geographical region, having to be produced in Ireland.
Bourbon is required to be produced only in the United States but the law doesn’t limit where in the states it’s produced. Though Kentucky leads the way bottling 95 percent of the world’s supply. Even though the technicalities get nitty gritty, the best way to sample the difference is a taste test. To get the best flavor from the bourbon serve it neat, as the cold brings out the aroma and flavor, while for whisky add a splash of water. From being aged in the oak barrels an oaky flavor remains in both liquors, while bourbon obtains a slight sweetness with general tasting notes of vanilla and caramel.
thebacklabel link: http://thebacklabel.com/difference-whiskey-bourbon/#ixzz4JzTmyzYT
Gov, You could well be right about BIVI moving up quickly, especially since their approach is already approved in Europe. However, I hope both stocks do well soon.
Better formatting in the email from BIVI:
BioVie's Lead Compound BIV201 Receives FDA Orphan-Drug Designation for the Treatment of Ascites
BEVERLY, MA--(Marketwired - September 09, 2016) - BioVie Inc. (OTC PINK: BIVI) (the "Company"), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today that the Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for BIV201 for the treatment of ascites due to all etiologies except cancer. BIV201 is the Company's new drug candidate being developed for ascites due to chronic liver cirrhosis.
"Orphan-drug designation represents a major milestone supporting the clinical development and eventual commercialization of BIV201 therapy. It recognizes the importance of pioneering a new therapeutic approach for this relatively small group of desperately ill patients," commented Jonathan Adams, BioVie CEO. "Additionally, it can help to accelerate our clinical development program, opens the door to special funding opportunities and tax credits, and could provide seven years of market exclusivity."
BioVie's clinical development team, comprised of five highly experienced pharmaceutical industry veterans and advised by worldwide leaders in liver disease, is currently focused on completing an investigational new drug (IND) application for BIV201. If accepted by the FDA, our new drug candidate could commence a US clinical trial in 2017. Once this goal is accomplished, BioVie will begin to explore other potential applications for BIV201 therapy. The active ingredient in BIV201 is a potent vasoconstrictor and this mechanism of action yields the potential to treat an array of life-threatening diseases, including type 1 hepatorenal syndrome (HRS), esophageal variceal bleeds, and sepsis.
For more information, please visit our website www.biovieinc.com.
About Liver Cirrhosis and Ascites
About one million Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th-leading cause of death due to disease in the US, killing an estimated 27,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity. Ascites is a common complication of advanced liver cirrhosis. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients may fail to respond to treatment as ascites worsens. This unfavorable prognosis represents a critical unmet medical need. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
About BioVie (formerly NanoAntibiotics)
BioVie Inc. is a development-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on commercializing BIV201, a novel approach to the treatment of ascites due to liver cirrhosis. In early 2016 the Company held a pre-investigational new drug ("pre-IND") meeting with the FDA, which provided guidance for an IND submission. The Company's new drug candidate could potentially commence US clinical trials as early as 2017.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie's need for, and the availability of, substantial capital in the future to fund its operations and research and development; and the risks that BioVie's compounds may experience delays or difficulties in commencing or completing clinical studies, may not successfully complete pre-clinical or clinical testing, or may not be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie's filings with the Securities and Exchange Commission under its former name. In addition to the risks described above and in BioVie's filings with the SEC, other unknown or unpredictable factors also could affect BioVie's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
BioVie's Lead Compound BIV201 Receives FDA Orphan-Drug Designation for the Treatment of Ascites
BY Market Wire
— 10:06 AM ET 09/09/2016
BEVERLY, MA -- (Marketwired) -- 09/09/16 -- BioVie Inc. ( BIVI
Loading... Loading...
) (the "Company"), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies, announced today that the Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for BIV201 for the treatment of ascites due to all etiologies except cancer. BIV201 is the Company's new drug candidate being developed for ascites due to chronic liver cirrhosis.
"Orphan-drug designation represents a major milestone supporting the clinical development and eventual commercialization of BIV201 therapy. It recognizes the importance of pioneering a new therapeutic approach for this relatively small group of desperately ill patients," commented Jonathan Adams, BioVie ( BIVI
Loading... Loading...
) CEO. "Additionally, it can help to accelerate our clinical development program, opens the door to special funding opportunities and tax credits, and could provide seven years of market exclusivity."
BioVie's ( BIVI
Loading... Loading...
) clinical development team, comprised of five highly experienced pharmaceutical industry veterans and advised by worldwide leaders in liver disease, is currently focused on completing an investigational new drug (IND) application for BIV201. If accepted by the FDA, our new drug candidate could commence a US clinical trial in 2017. Once this goal is accomplished, BioVie ( BIVI
Loading... Loading...
) will begin to explore other potential applications for BIV201 therapy. The active ingredient in BIV201 is a potent vasoconstrictor and this mechanism of action yields the potential to treat an array of life-threatening diseases, including type 1 hepatorenal syndrome (HRS), esophageal variceal bleeds, and sepsis.
For more information, please visit our website www.biovieinc.com.
About Liver Cirrhosis and Ascites
About one million Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th-leading cause of death due to disease in the US, killing an estimated 27,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity. Ascites is a common complication of advanced liver cirrhosis. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients may fail to respond to treatment as ascites worsens. This unfavorable prognosis represents a critical unmet medical need. US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
About BioVie ( BIVI
Loading... Loading...
) (formerly NanoAntibiotics)
BioVie Inc. ( BIVI
Loading... Loading...
) is a development-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on commercializing BIV201, a novel approach to the treatment of ascites due to liver cirrhosis. In early 2016 the Company held a pre-investigational new drug ("pre-IND") meeting with the FDA, which provided guidance for an IND submission. The Company's new drug candidate could potentially commence US clinical trials as early as 2017.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's ( BIVI
Loading... Loading...
) actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie ( BIVI
Loading... Loading...
) has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie's ( BIVI
Loading... Loading...
) need for, and the availability of, substantial capital in the future to fund its operations and research and development; and the risks that BioVie's ( BIVI
Loading... Loading...
) compounds may experience delays or difficulties in commencing or completing clinical studies, may not successfully complete pre-clinical or clinical testing, or may not be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie's ( BIVI
Loading... Loading...
) filings with the Securities and Exchange Commission under its former name. In addition to the risks described above and in BioVie's ( BIVI
Loading... Loading...
) filings with the SEC, other unknown or unpredictable factors also could affect BioVie's ( BIVI
Loading... Loading...
) results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements. BioVie ( BIVI
Loading... Loading...
) undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
BioVie Inc. ( BIVI
Loading... Loading...
)
Email contact
Source: BioVie Inc. ( BIVI
Loading... Loading...
)